Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 202

Similar articles for PubMed (Select 19420074)

1.

Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.

Wang L, Cheng C, Ko SY, Kong WP, Kanekiyo M, Einfeld D, Schwartz RM, King CR, Gall JG, Nabel GJ.

J Virol. 2009 Jul;83(14):7166-75. doi: 10.1128/JVI.00374-09. Epub 2009 May 6.

2.

Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.

Ko SY, Cheng C, Kong WP, Wang L, Kanekiyo M, Einfeld D, King CR, Gall JG, Nabel GJ.

J Virol. 2009 Jan;83(2):748-56. doi: 10.1128/JVI.01811-08. Epub 2008 Nov 5.

3.

Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier.

Domm W, Brooks L, Chung HL, Feng C, Bowers WJ, Watson G, McGrath JL, Dewhurst S.

Vaccine. 2011 Sep 16;29(40):7080-9. doi: 10.1016/j.vaccine.2011.07.008. Epub 2011 Jul 27.

4.

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.

Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Ledgerwood JE, Bailer RT, Mascola JR, Nabel GJ, Graham BS; VRC 009 Study Team; VRC 010 Study Team.

PLoS One. 2010 Feb 2;5(2):e9015. doi: 10.1371/journal.pone.0009015.

5.
6.

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system.

Lemiale F, Kong WP, Akyürek LM, Ling X, Huang Y, Chakrabarti BK, Eckhaus M, Nabel GJ.

J Virol. 2003 Sep;77(18):10078-87.

7.

A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice.

Buffa V, Negri DR, Leone P, Bona R, Borghi M, Bacigalupo I, Carlei D, Sgadari C, Ensoli B, Cara A.

J Gen Virol. 2006 Jun;87(Pt 6):1625-34.

PMID:
16690927
8.

Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.

Someya K, Xin KQ, Ami Y, Izumi Y, Mizuguchi H, Ohta S, Yamamoto N, Honda M, Okuda K.

Virology. 2007 Oct 25;367(2):390-7. Epub 2007 Jul 12.

9.

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA.

Nature. 2002 Jan 17;415(6869):331-5.

PMID:
11797011
11.

An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.

Lemiale F, Asefa B, Ye D, Chen C, Korokhov N, Humeau L.

Vaccine. 2010 Feb 23;28(8):1952-61. doi: 10.1016/j.vaccine.2009.10.089.

PMID:
20188251
12.

Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.

Casimiro DR, Bett AJ, Fu TM, Davies ME, Tang A, Wilson KA, Chen M, Long R, McKelvey T, Chastain M, Gurunathan S, Tartaglia J, Emini EA, Shiver J.

J Virol. 2004 Oct;78(20):11434-8.

13.

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL.

J Virol. 2005 Jan;79(2):771-9.

14.
15.

Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.

Lin SW, Hensley SE, Tatsis N, Lasaro MO, Ertl HC.

J Clin Invest. 2007 Dec;117(12):3958-70.

16.

Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.

Belyakov IM, Ahlers JD, Nabel GJ, Moss B, Berzofsky JA.

Virology. 2008 Nov 10;381(1):106-15. doi: 10.1016/j.virol.2008.08.019. Epub 2008 Sep 14.

17.

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.

Abaitua F, Rodríguez JR, Garzón A, Rodríguez D, Esteban M.

Virus Res. 2006 Mar;116(1-2):11-20. Epub 2005 Oct 7.

PMID:
16214252
18.

CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization.

Sundling C, Schön K, Mörner A, Forsell MN, Wyatt RT, Thorstensson R, Karlsson Hedestam GB, Lycke NY.

J Gen Virol. 2008 Dec;89(Pt 12):2954-64. doi: 10.1099/vir.0.2008/005470-0.

PMID:
19008380
19.

Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells.

Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, King CR, Nabel GJ.

PLoS Pathog. 2007 Feb;3(2):e25.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk